Inclusion Criteria:  Subject has provided written informed consent Subject is 18 years of age or older A unilateral HDSS score of 3 or 4 for each axilla A gravimetric measurement of at least 50 mg/5 min for women and 100 mg/5 min for men in at least one axilla. The contralateral axilla should not be below 40 mg (women) and 80 mg (men). Women of childbearing potential must be confirmed not pregnant by a negative u-HCG prior to study treatment and must use a safe contraceptive method at baseline.  Exclusion Criteria:  Subjects with generalized hyperhidrosis Medical condition or medications that may alter perspiration (e.g. metabolic, immunological or infectious diseases, antidepressants, opioids, adrenergic/cholinergic drugs) Daily use of systemic or topical antibiotics and/or steroids in axillae at the time of inclusion Topical treatments for axillary hyperhidrosis (anti-perspirants are allowed except for visit days) Abnormal skin (e.g. rash, infection, dermatitis) in the axilla at the time of inclusion Breast tissue in the axillae Treatment with Isotretinoin within the past 6 months Axillary laser or IPL treatment within the past 6 months Botulinum toxin-injections in the axillae within the past 12 months prior to baseline Known allergies to botulinum toxin, iodine, lidocaine or adrenaline Prior axillary surgery Limited motion in the shoulder joint or neurologic deficit in upper limb History of diseases resulting in muscle weakness (ALS, Lou Gehrig's), dysphagia (Myasthenia Gravis or Lambert Eaton Syndrome) or respiratory compromise Axillary lymph node enlargement or -removal or lymphedema in either upper limb History of hidradenitis suppurativa or history of reoccurring infections/abscesses History of breast cancer Electronic device implant If female; lactating, pregnant or planning on becoming pregnant during the study Non-eligibility at the discretion of the investigator (e.g. non-compliance, unavailability or other reasons the subject is not believed to be able to comply with the clinical trial protocol)